

Human 4-1BB ELISA
OD450nm
Log(ng/ml)
Urelumab
B31
B16
B125
B164
B210
Human IgG
Cyno 4-1BB ELISA
OD 450 nm
Log(ng/mL)
Urelumab
B31
B16
B125
B210
B164
Human IgG
Mouse 4-1BB ELISA
OD 450 nm
Log(ng/mL)
Urelumab
B31
B16
B125
B210
B164
Human IgG

FIG. 1



2000
1500
1000
500
0
MFI
-4
-2
0
2
4
Log [Conc.] / nM
Urelumab
B31-BiAb
B16-BiAb
B125-BiAb
B210-BiAb
B164-BiAb
Iso-con

FIG. 2



B31
B16
B125
B164
B210
Relative response
Time
s
0
250
500
50
100
25

FIG. 3



hOX40 ELISA
OD450nm
2.0
1.5
1.0
0.5
0.0
-4
-2
0
2
4
Log(ng/ml)
Ure
B31
B16
B125
B164
B210
Human IgG
hCD40 ELISA
OD450nm
2.0
1.5
1.0
0.5
0.0
-4
-2
0
2
4
Log(ng/ml)
Ure
B31
B16
B125
B164
B210
Human IgG

FIG. 4



150000
100000
50000
0
RLU
-6
-4
-2
0
2
4
Log [Conc.] / nM
Urelumab
B31
IgG
30000
20000
10000
0
RLU
-4
-2
0
2
4
Log [Conc.] / nM
Urelumab
B16
B125
B164
B210

FIG. 5



Claudin18.2-
3000
2000
1000
0
RLU
-4
-3
-2
-1
0
1
2
3
Log [Conc.]/ nM
Urelumab
B31-BiAb
B16-BiAb
B125-BiAb
B164-BiAb
B210-BiAb
iso-con
Claudin18.2+
15000
10000
5000
0
RLU
-4
-3
-2
-1
0
1
2
3
Log [Conc.]/ nM
Urelumab
B31-BiAb
B16-BiAb
B125-BiAb
B164-BiAb
B210-BiAb
iso-con

FIG. 6



100 nM
20 nM
4 nM
0.8 nM
0.16 nM
0.032 nM
IL-2 (ng/ml)
0
10
20
30
Claudin18.2-
Claudin18.2Low
Claudin18.2High
B31
B100
B106
B121
B164
B210
Iso-con

FIG. 7



Claudin18.2-
80000
60000
40000
20000
0
-20000
RLU
-2
-1
0
1
2
3
Log [Conc.] / nM
B-31
B31_V2
B31_V3
B31_V4
B31_V5
B31_V6
Claudin18.2+
40000
30000
20000
10000
0
-10000
RLU
-2
-1
0
1
2
3
Log [Conc.] / nM
B-31
B31_V2
B31_V3
B31_V4
B31_V5
B31_V6

FIG. 8




100 nM
20 nM
4 nM
0.8 nM
0.16 nM
0.032 nM
IL-2 (ng/ml)
0
10
20
30
Claudin18.2-
Claudin18.2Low
Claudin18.2High
B-31
B31_V2
B31_V3
B31_V4
B31_V5
B31_V6
Iso-con

FIG. 9


Tumor volume (mm3)
4000
3000
2000
1000
0
0
5
10
15
20
25
Days after administration
(Days)
PBS
Urelumab
B31
B16
B125
B164
B210



Tumor weight (mg)
4000
3000
2000
1000
0
**
****
***
**
****
****
PBS
Urelumab
B164
B210
B125
B16
B31

FIG. 10